References
- Suryadevara M, Domachowske JB. Epidemiology and seasonality of childhood respiratory syncytial virus infections in the tropics. Viruses. 2021; 13:696. doi: 10.3390/v13040696
- Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399:2047–64.
- Robert C, Welliver SR. Respiratory syncytial virus. In: Cherry J, Kaplan SL, Demmler-Harrison DJ, Steinbach W, Hotez PJ, Williams JV, editors. Feigin and Cherry’s textbook of pediatric infectious diseases. 9th ed. Philadelphia: Elsevier; 2025, p. 1865–82.
- Scheltema NM, Gentile A, Lucion F, Nokes DJ, Munywoki PK, Madhi SA, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017; 5:e984–91.
- Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of paediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016; 3:63–71.
- World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, September 2024: conclusions and recommendations. Wkly Epidemiol Rec. 2024; 99:719–40. [cited 2025 Apr 11]. Available from:
https://www.who.int/publications/i/item/who-wer9949-719-740 - GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024; 24:974–1002.
- Aikphaibul P, Theerawit T, Sophonphan J, Wacharachaisurapol N, Jitrungruengnij N, Puthanakit T. Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand. Influenza Other Respir Viruses. 2021; 15:64–71.
- Tan CJ, Patikorn C, Techasaensiri C, Pattanaprateep O, Chaiyakunapruk N. Economic and clinical outcomes of pediatric patients under two with respiratory syncytial virus infection in Thailand: a real-world retrospective cohort study. Pediatr Infect Dis J. 2023; 42:883–7.
- Park S, Lee H, Park JY, Choi S, Kim HJ, Bertizzolo L, et al. Trends in proportions of respiratory syncytial virus infections among reported respiratory tract infection cases in children aged 0 to 5 years in Western Pacific and Southeast Asia regions: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2025; 19:e70077. doi: 10.1111/irv.70077
- Tam CC, Yeo KT, Tee N, Lin R, Mak TM, Thoon KC, et al. Burden and cost of hospitalization for respiratory syncytial virus in young children, Singapore. Emerg Infect Dis. 2020; 26:1489–96.
- Yu J, Liu C, Xiao Y, Xiang Z, Zhou H, Chen L, et al. Respiratory syncytial virus seasonality, Beijing, China, 2007–2015. Emerg Infect Dis. 2019; 25:1127–35.
- Sitthikarnkha P, Uppala R, Niamsanit S, Sutra S, Thepsuthammarat K, Techasatian L, et al. Burden of respiratory syncytial virus related acute lower respiratory tract infection in hospitalized Thai children: a 6-year national data analysis. Children (Basel). 2022; 9:1990.
- Bunthi C, Rhodes J, Thamthitiwat S, Higdon MM, Chuananon S, Amorninthapichet T, et al. Etiology and clinical characteristics of severe pneumonia among young children in Thailand: Pneumonia Etiology Research for Child Health (PERCH) case-control study findings, 2012–2013. Pediatr Infect Dis J. 2021; 40:S91–100.
- Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390:946–58.
- Lai CC, Hsueh PR. An overview on disease burden and management of respiratory syncytial virus infections in older adults in the Asia-Pacific region. Rev Med Virol. 2024; 34:e70003. doi: 10.1002/rmv.70003
- Lam TT, Tang JW, Lai FY, Zaraket H, Dbaibo G, Bialasiewicz S, et al. Comparative global epidemiology of influenza, respiratory syncytial and parainfluenza viruses, 2010–2015. J Infect. 2019; 79:373–82.
- Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et al. Defining the seasonality of respiratory syncytial virus around the world: national and subnational surveillance data from 12 countries. Influenza Other Respir Viruses. 2021; 15:732–41.
- Pastor-Barriuso R, Núñez O, Monge S; Nirsevimab Effectiveness Study Collaborators. Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season. Euro Surveill. 2025; 30:2500040. doi: 10.2807/1560-7917.ES.2025.30.6.2500040
- Khor CS, Sam IC, Hooi PS, Quek KF, Chan YF. Epidemiology and seasonality of respiratory viral infections in hospitalized children in Kuala Lumpur, Malaysia: a retrospective study of 27 years. BMC Pediatr. 2012; 12:32. doi: 10.1186/1471-2431-12-32
- Chan PW, Chew FT, Tan TN, Chua KB, Hooi PS. Seasonal variation in respiratory syncytial virus chest infection in the tropics. Pediatr Pulmonol. 2002; 34:47–51.
- Fry AM, Chittaganpitch M, Baggett HC, Peret TC, Dare RK, Sawatwong P, et al. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand. PLoS One. 2010; 5:e15098. doi: 10.1371/journal.pone.0015098
- Li M, Cong B, Wei X, Wang Y, Kang L, Gong C, et al. Characterising the changes in RSV epidemiology in Beijing, China during 2015–2023: results from a prospective, multi-centre, hospital-based surveillance and serology study. Lancet Reg Health West Pac. 2024; 45:101050.
- Hause AM, Avadhanula V, Maccato ML, Pinell PM, Bond N, Santarcangelo P, et al. Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women. Vaccine. 2019; 37:3464–71.
- Chu HY, Katz J, Tielsch J, Khatry SK, Shrestha L, LeClerq SC, et al. Clinical presentation and birth outcomes associated with respiratory syncytial virus infection in pregnancy. PLoS One. 2016; 11:e0152015. doi: 10.1371/journal.pone.0152015
- Wheeler SM, Dotters-Katz S, Heine RP, Grotegut CA, Swamy GK. Maternal effects of respiratory syncytial virus infection during pregnancy. Emerg Infect Dis. 2015; 21:1951–5.
- Regan AK, Klein NP, Langley G, Drews SJ, Buchan S, Ball S, et al. Respiratory syncytial virus hospitalization during pregnancy in 4 high-income countries, 2010–2016. Clin Infect Dis. 2018; 67:1915–8.
- Riccò M, Ferraro P, Corrado S, Zaniboni A, Satta E, Ranzieri S. Respiratory syncytial virus in pregnant women: systematic review and meta-analysis. Women. 2022; 2:147–60.
- Manti S, Cuppari C, Lanzafame A, Salpietro C, Betta P, Leonardi S, et al. Detection of respiratory syncytial virus (RSV) at birth in a newborn with respiratory distress. Pediatr Pulmonol. 2017; 52:E81–4.
- Manti S, Esper F, Alejandro-Rodriguez M, Leonardi S, Betta P, Cuppari C, et al. Respiratory syncytial virus seropositivity at birth is associated with adverse neonatal respiratory outcomes. Pediatr Pulmonol. 2020; 55:3074–9.
- Munywoki PK, Koech DC, Agoti CN, Cane PA, Medley GF, Nokes DJ. Continuous invasion by respiratory viruses observed in rural households during a respiratory syncytial virus seasonal outbreak in coastal Kenya. Clin Infect Dis. 2018; 67:1559–67.
- Girma A. Biology of human respiratory syncytial virus: current perspectives in immune response and mechanisms against the virus. Virus Res. 2024; 350:199483. doi: 10.1016/j.virusres.2024.199483
- Russell CD, Unger SA, Walton M, Schwarze J. The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev. 2017; 30:481–502.
- Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015; 191:1040–9.
- Clements T, Rice TF, Vamvakas G, Barnett S, Barnes M, Donaldson B, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. Front Immunol. 2020; 11:1920. doi: 10.3389/fimmu.2020.01920
- Rumfelt KE, Pike M, Stolarczuk JE, Lekander A, Lauring AS, Eckert LO, et al. Maternal-infant respiratory syncytial virus and influenza a virus antibody transfer in preterm and full-term infants. Open Forum Infect Dis. 2024; 12:ofae723. doi: 10.1093/ofid/ofae723
- Pasittungkul S, Thongpan I, Vichaiwattana P, Thongmee T, Klinfueng S, Suntronwong N, et al. High seroprevalence of antibodies against human respiratory syncytial virus and evidence of respiratory syncytial virus reinfection in young children in Thailand. Int J Infect Dis. 2022; 125:177–83.
- Cinicola B, Conti MG, Terrin G, Sgrulletti M, Elfeky R, Carsetti R, et al. The protective role of maternal immunization in early life. Front Pediatr. 2021; 9:638871. doi: 10.3389/fped.2021.638871
- Vassilopoulou E, Agostoni C, Feketea G, Alberti I, Gianni ML, Milani GP. The role of breastfeeding in acute respiratory infections in infancy. Pediatr Infect Dis J. 2024; 43:1090–9.
- Lamberti LM, Zakarija-Grković I, Fischer Walker CL, Theodoratou E, Nair H, Campbell H, et al. Breastfeeding for reducing the risk of pneumonia morbidity and mortality in children under two: a systematic literature review and meta-analysis. BMC Public Health. 2013; 13(Suppl 3):S18. doi: 10.1186/1471-2458-13-S3-S18
- Mineva GM, Purtill H, Dunne CP, Philip RK. Impact of breastfeeding on the incidence and severity of respiratory syncytial virus (RSV)-associated acute lower respiratory infections in infants: a systematic review highlighting the global relevance of primary prevention. BMJ Glob Health. 2023; 8:e009693. doi: 10.1136/bmjgh-2022-009693
- von Linstow ML, Høgh M, Nordbø SA, Eugen-Olsen J, Koch A, Høgh B. A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life. Eur J Pediatr. 2008; 167:1125–33.
- Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J. 2004; 23:815–20.
- Fischer L, Okanmelu E, Theurich MA. Call to include breastfeeding as a synergistic approach to vaccines for prevention of respiratory syncytial virus disease. Int Breastfeed J. 2025; 20:12. doi: 10.1186/s13006-025-00705-9
- Tonon KM, Chutipongtanate S, Morrow AL, Newburg DS. Human milk oligosaccharides and respiratory syncytial virus infection in infants. Adv Nutr. 2024; 15:100218. doi: 10.1016/j.advnut.2024.100218
- Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019; 17:233–45.
- Carvajal JJ, Avellaneda AM, Salazar-Ardiles C, Maya JE, Kalergis AM, Lay MK. Host components contributing to respiratory syncytial virus pathogenesis. Front Immunol. 2019; 10:2152. doi: 10.3389/fimmu.2019.02152
- Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015; 5:020416. doi: 10.7189/jogh.05.020416
- Shi T, Vennard S, Mahdy S, Nair H; RESCEU investigators. Risk factors for poor outcome or death in young children with respiratory syncytial virus–associated acute lower respiratory tract infection: a systematic review and meta-analysis. J Infect Dis. 2022; 226(Suppl_1):S10–6.
- Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet. 2017; 389:211–24.
- Jha A, Jarvis H, Fraser C, Openshaw PJM. Respiratory syncytial virus. In: Hui DS, Rossi GA, Johnston SL, editors. SARS, MERS and other viral lung infections. Sheffield (UK): European Respiratory Society; 2016. Chapter 5.
- Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015; 53:3738–49.
- Schuh S, Lalani A, Allen U, Manson D, Babyn P, Stephens D, et al. Evaluation of the utility of radiography in acute bronchiolitis. J Pediatr. 2007; 150:429–33.
- Guo W, Wang J, Sheng M, Zhou M, Fang L. Radiological findings in 210 paediatric patients with viral pneumonia: a retrospective case study. Br J Radiol. 2012; 85:1385–9.
- Sheikh Z, Potter E, Li Y, Cohen RA, Dos Santos G, Bont L, et al. Validity of clinical severity scores for respiratory syncytial virus: a systematic review. J Infect Dis. 2024; 229(Suppl_1):S8–17.
- Golan-Tripto I, Goldbart A, Akel K, Dizitzer Y, Novack V, Tal A. Modified Tal Score: validated score for prediction of bronchiolitis severity. Pediatr Pulmonol. 2018; 53:796–801.
- Chin HJ, Seng QB. Reliability and validity of the respiratory score in the assessment of acute bronchiolitis. Malays J Med Sci. 2004; 11:34–40.
- Caserta MT, Qiu X, Tesini B, Wang L, Murphy A, Corbett A, et al. Development of a Global Respiratory Severity Score for respiratory syncytial virus infection in infants. J Infect Dis. 2017; 215:750–6.
- Miyaji Y, Sugai K, Nozawa A, Kobayashi M, Niwa S, Tsukagoshi H, et al. Pediatric Respiratory Severity Score (PRESS) for respiratory tract infections in children. Austin Virol Retrovirol. 2015; 2:1009.
- Gsenger J, Bruckner T, Ihling CM, Rehbein RM, Schnee SV, Hoos J, et al. RSV-CLASS – Clinical Assessment Severity Score: an easy-to-use clinical disease severity score for respiratory syncytial virus infection in hospitalized children. J Med Virol. 2023; 95:e28541. doi: 10.1002/jmv.28541
- Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015; 3:888–900.
- Simões EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018; 7:87–120.
- Kepreotes E, Whitehead B, Attia J, Oldmeadow C, Collison A, Searles A, et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. Lancet. 2017; 389:930–9.
- Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018; 378:1121–31.
- Tejada S, Martinez-Reviejo R, Karakoc HN, Peña-López Y, Manuel O, Rello J. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis. Adv Ther. 2022; 39:4037–51.
- Feng Z, Xie Z, Xu L. Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection. Virol Sin. 2025; 40:147–56.
- Zhao S, Shang Y, Yin Y, Zou Y, Xu Y, Zhong L, et al. Ziresovir in hospitalized infants with respiratory syncytial virus infection. N Engl J Med. 2024; 391:1096–107.
- Zhang H, Zhao W, Zhang X, Zhang L, Guo R, Huang H, et al. Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up. Lancet Child Adolesc Health. 2025; 9:325–36.
- Bont L, Steijn M, Van Aalderen WM, Brus F, Th Draaisma JM, Van Diemen-Steenvoorde RA, et al. Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax. 2004; 59:512–6.
- Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS Jr, Dupont WD, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023; 401:1669–80.
- Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J. 2013; 32:820–6.
- Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics. 2007; 25:55–71.
- Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ. 2009; 12:301–8.
- Yu T, Padula WV, Yieh L, Gong CL. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks’ gestation in the United States. Pediatr Neonatol. 2024; 65:152–8.
- Suryadevara M. Passive immunization strategies to prevent severe respiratory syncytial virus infection among newborns and young infants. J Pediatric Infect Dis Soc. 2024; 13(Suppl_2):S110–4.
- Mahase E. FDA pauses all infant RSV vaccine trials after rise in severe illnesses. BMJ. 2024; 387:q2852. doi: 10.1136/bmj.q2852
- Karron RA, Luongo C, Woods S, Oliva J, Collins PL, Buchholz UJ, et al. Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/ΔNS2/1030s in RSV-seronegative young children. J Infect Dis. 2024; 229:346–54.
- Pecenka C, Sparrow E, Feikin DR, Srikantiah P, Darko DM, Karikari-Boateng E, et al. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children. Lancet. 2024; 404:1157–70.
- Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023; 388:1451–64.
- Infectious Disease Association of Thailand. Recommended adult and elderly immunization schedule. 2025. [cited 2025 Apr 11]. Available from:
https://idthai.org/Contents/Views/?d=%2117%219%21%211046 . - HAS. RSV infection vaccination recommendation for pregnant women. 2024. [cited 2025 Apr 11]. Available from:
https://www.has-sante.fr/jcms/p_3505344/en/rsv-infection-vaccination-recommendation-for-pregnant-women . - Gentile A, Juárez MDV, Lucion MF, Ensinck G, Lopez O, Melonari P, et al. Respiratory syncytial virus epidemiology in Argentina: from COVID-19 pandemic to the maternal immunization strategy. Pediatr Infect Dis J. 2025; 44:S23–6.
- Pérez Marc G, Vizzotti C, Fell DB, Di Nunzio L, Olszevicki S, Mankiewicz SW, et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study. Lancet Infect Dis. 2025:S1473-3099(25)00156-2.
- The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102(3 Pt 1):531–7.
- Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003; 143:532–40.
- Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022; 386:837–46.
- Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023; 389:2425–35.
- Noor A, Krilov LR. A historical perspective on respiratory syncytial virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy. J Pediatric Infect Dis Soc. 2024; 13(Suppl_2):S103–9.
- Domachowske JB. New and emerging passive immunization strategies for the prevention of RSV infection during infancy. J Pediatric Infect Dis Soc. 2024; 13(Suppl_2):S115–24.
- Mejias A, Ramilo O. RSV prevention within reach for older infants and toddlers: the role of active immunization. J Pediatric Infect Dis Soc. 2024; 13(Suppl_2):S125–30.
- Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020; 383:415–25.
- Madhi SA, Simões EAF, Acevedo A, Novoa Pizarro JM, Shepard JS, Railkar RA, et al. A phase 1b/2a trial of a half-life extended respiratory syncytial virus neutralizing antibody, clesrovimab, in healthy preterm and full-term infants. J Infect Dis. 2025; 231:e478–87.
- Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022; 386:892–4.
- Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023; 388:1533–4.
- Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccin Immunother. 2021; 17:1867–72.
- Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, et al. Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: a systematic review. Am J Perinatol. 2024; 41:e1107–15.
- Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017; 36:699–704.
- Yeo KT, Yung CF, Khoo PC, Saffari SE, Sng JSP, How MS, et al. Effectiveness of palivizumab against respiratory syncytial virus hospitalization among preterm infants in a setting with year-round circulation. J Infect Dis. 2021; 224:279–87.
- Jabagi MJ, Cohen J, Bertrand M, Chalumeau M, Zureik M. Nirsevimab effectiveness at preventing RSV-related hospitalization in infants. NEJM Evid. 2025; 4:EVIDoa2400275. doi: 10.1056/EVIDoa2400275
- Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024; 24:817–28.
- Assad Z, Romain AS, Aupiais C, Shum M, Schrimpf C, Lorrot M, et al. Nirsevimab and hospitalization for RSV bronchiolitis. N Engl J Med. 2024; 391:144–54.
- Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, et al. Respiratory syncytial virus disease burden and nirsevimab effectiveness in young children from 2023–2024. JAMA Pediatr. 2025; 179:179–87.
- Sun M, Lai H, Na F, Li S, Qiu X, Tian J, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023; 6:e230023. doi: 10.1001/jamanetworkopen.2023.0023
- Merck. U.S. ACIP recommends use of Merck’s ENFLONSIA (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age born during or entering their first RSV season. [cited 2025 June 28]. Available from:
https://www.merck.com/news/acip-recommends-use-of-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-younger-than-8-months-of-age/ . - Bugden S, Mital S, Nguyen HV. Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada. BMC Med. 2025; 23:102. doi: 10.1186/s12916-025-03928-z
- Brown R, Tiggelaar S, Tsoi B, Cromwell I. Cost-effectiveness of nirsevimab for the prevention of respiratory syncytial virus infection in infants. CADTH health technology review. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2023. Report No: HE0045.